Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Franck Emmanuel NicoliniStephanie DulucqLisa BoureauPascale Cony-MakhoulAude CharbonnierMartine Escoffre-BarbeFrançoise Rigal-HuguetValérie CoiteuxBruno VaretViviane DubruillePascal LenainPhilippe RousselotDelphine ReaAgnès Guerci-BreslerLaurence LegrosJixing LiuMartine GardembasJean-Christophe IanottoPascal TurlureHyacinthe A Johnson-AnsahJuliana MartiniucHenry JardelBertrand JolyPatricia ZunicTawfiq HenniBruno VillemagneMarc G BergerEmilie CayssialsFrançois GuilhotFabrice LarosaJoëlle GuilhotGabriel EtienneFrançois-Xavier MahonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
We conclude that the duration of TKI and residual leukemic cell load as determined by ddPCR are key factors for predicting successful treatment-free remission for patients with de novo chronic phase CML.See related commentary by Yan et al., p. 6561.
Keyphrases